



सत्यमेव जयते

प्रोफेसर (डा.) बलराम भार्गव, पदम श्री

एमडी, डीएम, एफआरसीपी (जी.), एफआरसीपी (ई.), एफएसीसी,
एफएएचए, एफएएमएस, एफएनएएस, एफएएससी, एफ.एन.ए., डी.एस.सी.

सचिव, भारत सरकार

स्वास्थ्य अनुसंधान विभाग
स्वास्थ्य एवं परिवार कल्याण मंत्रालय एवं
महानिदेशक, आई सी एम आर

Prof. (Dr.) Balram Bhargava, Padma Shri

MD, DM, FRCP (Glasg.), FRCP (Edin.),
FACC, FAHA, FAMS, FNAsc, FASc, FNA, DSc

Secretary to the Government of India

Department of Health Research
Ministry of Health & Family Welfare &
Director-General, ICMR



icmr
INDIAN COUNCIL OF
MEDICAL RESEARCH
Serving the nation since 1911

भारतीय आयुर्विज्ञान अनुसंधान परिषद

स्वास्थ्य अनुसंधान विभाग
स्वास्थ्य एवं परिवार कल्याण मंत्रालय
भारत सरकार
वी. रामलिंगस्वामी भवन, अंसारी नगर
नई दिल्ली - 110 029

Indian Council of Medical Research

Department of Health Research
Ministry of Health & Family Welfare
Government of India
V. Ramalingaswami Bhawan, Ansari Nagar
New Delhi - 110 029

D.O. No. Secy.(DHR)/DG,ICMR-2020
Dated, the 17th March, 2020

Dear Ms. Sudan

I am enclosing herewith revised advisory strategy of COVID 19 testing in India dated 17th March, 2020. You are requested to kindly place on your website.

With kind regards,

Yours sincerely,

(Balram Bhargava)

Ms. Preeti Sudan

Secretary (Health & F. W.)
Ministry of Health & Family Welfare
Nirman Bhawan
New Delhi- 110011.

**INDIAN COUNCIL OF MEDICAL RESEARCH
DEPARTMENT OF HEALTH RESEARCH
Strategy of COVID19 testing in India (17/03/2020):**

Background:

WHO declared an outbreak of febrile respiratory illness of unknown etiology in December 2019 from Wuhan, Hubei province of China. Since its emergence, the disease has rapidly spread to neighboring provinces of China as well 151 other countries mainly through International travel. Infection is spread through droplets of an infected patient generated by coughing and sneezing or through prolonged contact with infected patients.

Currently, India has witnessed only imported cases of COVID19 and limited local transmission from imported cases to their immediate contacts. Community transmission of the disease has not been documented till now. If community transmission is documented, the above testing strategy will undergo changes to evolve into stage appropriate testing strategy.

Objectives:

- To contain the spread of infection / community transmission of COVID19 by improving access.
- To provide free of cost and reliable diagnosis to all individuals **meeting the inclusion criteria of COVID19 testing.**
- To avoid indiscriminate testing and reducing panic and optimally utilize the resources of the country and scale up facilities for testing.

Current scenario:

- All individuals **requiring** to be tested are being offered at no cost.
- Accessibility and availability of the test is being increased every day by adding optimum numbers of testing laboratories every week.
- Currently, the cost of the first step screening assay is INR 1500 and additional confirmatory assays is INR 3000.
- As a part of the laboratory expansion process, ICMR has engaged with non-ICMR / MOHFW Govt. laboratories to initiate testing facilities. This includes CSIR, DBT, DRDO, Govt. Medical Colleges etc.
- ICMR is also engaging with high-quality private laboratories that includes NABL accredited labs to understand the modalities of increasing access to the test while ensuring appropriate safeguards.
- ICMR is operationalizing already existing high throughput diagnostic systems (upto 1400 samples per day) to exponentially augment the testing capacity in heavily overloaded states. It is proposed to install high throughput systems in atleast 5 locations (with possibility of scale-up to 10 locations) on an urgent basis.
- ICMR-NIV, Pune has already placed orders to augment the existing stockpile of reagents to 1 million tests which would be available soon. WHO has also been requested to provide additional 1 million probes for testing.
- Advisory for testing are being reviewed and updated periodically (09/03/2020 and 16/03/2020). The testing strategy is reviewed by a high-level Expert Committee constituted by Secretary DHR & DG, ICMR and Chaired by Prof, Randeep Guleria, Director, All India Institute of Medical Sciences, Delhi.